Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study

Safety profiles of oral PI3K inhibitors have resulted in US FDA black box warnings regarding fatal/serious toxicities. The approved intravenous PI3K inhibitor copanlisib has low incidence of severe toxicities and no black box warnings, but chronic treatment effects were unknown. We provide an update on safety and efficacy of copanlisib with a minimum 2‐year follow‐up of the CHRONOS‐1 study. A total of 142 patients with histologically confirmed indolent B‐cell lymphoma who had relapsed after or were refractory to ≥2 prior treatments received intravenous copanlisib 60 mg on days 1, 8, and 15 (28‐day cycle). The primary efficacy endpoint was objective response rate (ORR) after ≥4 cycles (independent assessment). The predominant histology was follicular lymphoma (n = 104). The ORR was 60.6% (seven additional complete responses since primary analysis). Secondary endpoints of median duration of response, progression‐free survival, and overall survival were 14.1 months (median follow‐up, 16.1 months), 12.5 months (median follow‐up, 14.0 months), and 42.6 months (median follow‐up, 31.5 months), respectively. Median safety follow‐up was 6.7 months; 26% of patients received treatment for >1 year. Common treatment‐emergent adverse events (TEAEs) (all grade/grade 3/grade 4) were transient hyperglycemia (50.0%/33.1%/7.0%), diarrhea (35.2%/8.5%/0%), transient hypertension (29.6%/23.9%/0%), and neutropenia (28.9%/9.2%/14.8%). Serious AEs were largely unchanged, with no new cases of pneumonitis (4.2%), diarrhea (2.8%), or grade 5 events. Note, TEAEs showed no evidence for increased incidence or worsening following longer exposure in patients treated >1 year. Long‐term follow‐up of patients with relapsed/refractory indolent B‐cell lymphoma treated with intravenous copanlisib demonstrated durable, enhanced responses without evidence of worsening TEAEs, as reported for orally administered PI3K inhibitors.

[1]  G. Salles,et al.  On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors , 2019, Molecular Cancer Therapeutics.

[2]  H. Rugo,et al.  Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer , 2019, The New England journal of medicine.

[3]  I. Flinn,et al.  DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  I. Flinn,et al.  Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 study , 2018, American journal of hematology.

[5]  I. Flinn,et al.  Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. , 2018, The Lancet. Oncology.

[6]  M. Ghielmini,et al.  Corrigendum: Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [Ann Oncol, 27(Suppl 5), (2016), (v83-v90)] doi: 10.1093/annonc/mdw400 , 2017 .

[7]  Jonathon B. Cohen,et al.  PI3K Inhibitors: Understanding Toxicity Mechanisms and Management. , 2017, Oncology.

[8]  G. Lenz,et al.  Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Bociek,et al.  Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma , 2017, Haematologica.

[10]  P. Zinzani,et al.  Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  F. Toledo,et al.  First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Ningshu Liu,et al.  Discovery and SAR of Novel 2,3‐Dihydroimidazo[1,2‐c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80‐6946) , 2016, ChemMedChem.

[13]  E. Winer,et al.  A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast Cancer , 2016, Clinical Cancer Research.

[14]  J. Leonard,et al.  Idelalisib-associated Colitis: Histologic Findings in 14 Patients , 2015, The American journal of surgical pathology.

[15]  V. Gandhi,et al.  The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL , 2015, Leukemia.

[16]  A. Zelenetz,et al.  Management of adverse events associated with idelalisib treatment: expert panel opinion , 2015, Leukemia & lymphoma.

[17]  E. Van Cutsem,et al.  A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors , 2014, Clinical Cancer Research.

[18]  M. Ghielmini,et al.  Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  G. Salles,et al.  PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. , 2014, The New England journal of medicine.

[20]  G. Salles,et al.  Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL) , 2013 .

[21]  A. Haegebarth,et al.  BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models , 2013, Molecular Cancer Therapeutics.

[22]  J. Baselga,et al.  Abstract LB-64: GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study. , 2013 .

[23]  M. Davids,et al.  Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia. , 2013, Hematology/oncology clinics of North America.

[24]  J. Berlin,et al.  Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study , 2012 .

[25]  S. Treon,et al.  Report from the Sixth International Workshop on Waldenström's Macroglobulinemia. , 2011, Clinical lymphoma, myeloma & leukemia.

[26]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Robbie Loewith,et al.  A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling , 2006, Cell.

[28]  M Schemper,et al.  A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.